Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19 : A real-life experience
© 2023 Wiley Periodicals LLC..
Regardless of vaccination status, progression to severe coronavirus disease 2019 (COVID-19) is still a relevant cause of morbidity among immunocompromised patients. Despite the proven efficacy of nirmatrelvir/ritonavir (NMV/r), concerns remain regarding the potential for drug-to-drug interactions (DDIs) and the safety in this at-risk population. We aimed to evaluate the clinical outcomes of immunocompromised patients treated with NMV/r, as well as the occurrence of DDIs and treatment-emergent adverse events (TEAEs). This retrospective observational study included all the patients with some form of immunosuppression and laboratory-confirmed COVID-19 that received NMV/r at our center from April to August 2022. The main outcome was worsening of the clinical status (increase of ≥1 point from baseline in a validated clinical progression scale) by Days +7 and +28 after the initiation of therapy. Safety outcomes included the rates of any TEAE and potentially severe DDIs. We included 110 patients. Main causes of immunosuppression were hematological malignancy (58.2%) (mainly multiple myeloma [22.7%] and non-Hodgkin lymphoma [13.6%]), active chemotherapy (30.0%) and hematopoietic stem cell transplantation (14.5%). Clinical worsening by Days +7 and +28 was observed in four (3.6%) and five patients (4.5%), respectively. Only one patient had a positive SARS-CoV-2 polymerase chain reaction test at Day +28. At least one potentially severe DDI was observed in 56.4% of the patients. The rate of attributable TEAEs was 10.9%, although only two patients (1.8%) required premature discontinuation of NMV/r. Early initiation of NMV/r therapy should be considered in immunocompromised patients with COVID-19, with particular attention to interacting medications.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
---|---|
Enthalten in: |
Journal of medical virology - 95(2023), 9 vom: 15. Sept., Seite e29082 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Caso, José María [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 07.09.2023 Date Revised 09.09.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1002/jmv.29082 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM361695179 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM361695179 | ||
003 | DE-627 | ||
005 | 20231226085702.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jmv.29082 |2 doi | |
028 | 5 | 2 | |a pubmed24n1205.xml |
035 | |a (DE-627)NLM361695179 | ||
035 | |a (NLM)37671852 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Caso, José María |e verfasserin |4 aut | |
245 | 1 | 0 | |a Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19 |b A real-life experience |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.09.2023 | ||
500 | |a Date Revised 09.09.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 Wiley Periodicals LLC. | ||
520 | |a Regardless of vaccination status, progression to severe coronavirus disease 2019 (COVID-19) is still a relevant cause of morbidity among immunocompromised patients. Despite the proven efficacy of nirmatrelvir/ritonavir (NMV/r), concerns remain regarding the potential for drug-to-drug interactions (DDIs) and the safety in this at-risk population. We aimed to evaluate the clinical outcomes of immunocompromised patients treated with NMV/r, as well as the occurrence of DDIs and treatment-emergent adverse events (TEAEs). This retrospective observational study included all the patients with some form of immunosuppression and laboratory-confirmed COVID-19 that received NMV/r at our center from April to August 2022. The main outcome was worsening of the clinical status (increase of ≥1 point from baseline in a validated clinical progression scale) by Days +7 and +28 after the initiation of therapy. Safety outcomes included the rates of any TEAE and potentially severe DDIs. We included 110 patients. Main causes of immunosuppression were hematological malignancy (58.2%) (mainly multiple myeloma [22.7%] and non-Hodgkin lymphoma [13.6%]), active chemotherapy (30.0%) and hematopoietic stem cell transplantation (14.5%). Clinical worsening by Days +7 and +28 was observed in four (3.6%) and five patients (4.5%), respectively. Only one patient had a positive SARS-CoV-2 polymerase chain reaction test at Day +28. At least one potentially severe DDI was observed in 56.4% of the patients. The rate of attributable TEAEs was 10.9%, although only two patients (1.8%) required premature discontinuation of NMV/r. Early initiation of NMV/r therapy should be considered in immunocompromised patients with COVID-19, with particular attention to interacting medications | ||
650 | 4 | |a Observational Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a antiviral therapy | |
650 | 4 | |a immunocompromised patients | |
650 | 4 | |a interactions | |
650 | 4 | |a nirmatrelvir/ritonavir | |
650 | 4 | |a outcomes | |
650 | 4 | |a safety | |
650 | 7 | |a nirmatrelvir |2 NLM | |
650 | 7 | |a 7R9A5P7H32 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
700 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
700 | 1 | |a López-Medrano, Francisco |e verfasserin |4 aut | |
700 | 1 | |a Caro-Teller, José Manuel |e verfasserin |4 aut | |
700 | 1 | |a Lizasoain, Manuel |e verfasserin |4 aut | |
700 | 1 | |a San-Juan, Rafael |e verfasserin |4 aut | |
700 | 1 | |a Fayos Pérez, Marina |e verfasserin |4 aut | |
700 | 1 | |a Rodríguez-Goncer, Isabel |e verfasserin |4 aut | |
700 | 1 | |a Silva, Jose Tiago |e verfasserin |4 aut | |
700 | 1 | |a Aguado, José María |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 95(2023), 9 vom: 15. Sept., Seite e29082 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
773 | 1 | 8 | |g volume:95 |g year:2023 |g number:9 |g day:15 |g month:09 |g pages:e29082 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.29082 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 95 |j 2023 |e 9 |b 15 |c 09 |h e29082 |